Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW PEDINOFF

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1033116801
CMS profile
364149
Location
SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,610.81

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,337.50 1
Food and Beverage $273.31 20

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW PEDINOFF

NPI 1033116801 · CMS profile ID 364149

Allopathic & Osteopathic Physicians / Allergy & Immunology

SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1033116801?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $2,610.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $14.3012/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809612971 CMS
Covis Pharma GmBH $14.8812/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847687431 CMS
Teva Pharmaceuticals USA, Inc. $13.6810/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839673583 CMS
Merck Sharp & Dohme Corporation $11.3810/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848536879 CMS
Covis Pharma GmBH $15.3010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844396763 CMS
Covis Pharma GmBH $15.3010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847687427 CMS
Pharming Healthcare, Inc. $12.0710/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820560129 CMS
AstraZeneca Pharmaceuticals LP $14.9909/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829616507 CMS
AstraZeneca Pharmaceuticals LP $11.3709/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830020951 CMS
Phadia US Inc. $13.4909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 770178172 CMS
kaleo, Inc. $14.0909/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832125253 CMS
AstraZeneca Pharmaceuticals LP $11.4609/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829523589 CMS
AstraZeneca Pharmaceuticals LP $11.5507/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829874629 CMS
Optinose US, Inc. $13.2207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851670791 CMS
AstraZeneca Pharmaceuticals LP $14.9907/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829937615 CMS
GlaxoSmithKline, LLC. $14.8906/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802641855 CMS
AstraZeneca Pharmaceuticals LP $14.9906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829607709 CMS
Novartis Pharmaceuticals Corporation $2,337.5006/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813156261 CMS
GlaxoSmithKline, LLC. $14.7205/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802233989 CMS
kaleo, Inc. $14.4103/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832125251 CMS
GlaxoSmithKline, LLC. $12.2303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802217565 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $14.87 1
PY2021 $2,610.81 21
PY2022 $282.79 24
PY2023 $186.57 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,078.66 3
PY2023 Principal investigator $155,562.82 28
PY2022 Principal investigator $467,597.19 23
PY2021 Principal investigator $355,310.51 36
PY2020 Principal investigator $554,325.08 51
PY2019 Principal investigator $722,989.71 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $31.00 12/01/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249901
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,627.58 11/15/2021 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REMIBRUTINIB (LOU064) TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY FOR 52 WEEKS IN ADULT CHRONIC SPONTANEOUS URTICARIA (CSU) PATIENTS INADEQUATELY CONTROLLED BY H1-ANTIHISTAMINES No dispute reported 06/30/2026 800641931
Principal investigator 1 Allergan, Inc. $2,657.15 11/12/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,500.00 11/12/2021 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home No dispute reported 06/30/2026 793113921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,019.50 11/12/2021 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home No dispute reported 06/30/2026 793113923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,509.75 11/12/2021 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home No dispute reported 06/30/2026 793113925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 11/12/2021 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home No dispute reported 06/30/2026 793113927
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 11/12/2021 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806267403
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,400.00 11/12/2021 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806267407
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 11/12/2021 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806267409
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $31.00 11/01/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249897
Principal investigator 1 Allergan, Inc. $8,450.25 10/13/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004427
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $31.00 10/01/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249893
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $779.13 09/27/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249953
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $389.46 09/27/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249955
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $782.07 09/27/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249959
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,387.22 09/27/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249963
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,139.68 09/27/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249965
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 09/17/2021 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806267207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,500.00 09/17/2021 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806267211
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 09/17/2021 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806267213
Principal investigator 1 Allergan, Inc. $15,370.05 09/14/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004425
Principal investigator 1 Allergan, Inc. $10,793.90 08/13/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004423
Principal investigator 1 Allergan, Inc. $14,552.10 07/13/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004421
Principal investigator 1 Allergan, Inc. $22,439.00 06/15/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004419
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $67,266.00 06/14/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806249943
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,603.00 06/14/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806249945
Principal investigator 1 Allergan, Inc. $19,530.10 05/17/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004417
Principal investigator 1 Allergan, Inc. $4,998.90 04/13/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004415
Principal investigator 1 Allergan, Inc. $7,204.80 03/15/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004413
Principal investigator 1 Amphastar Pharmaceuticals, Inc. $32,097.32 02/18/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients No dispute reported 06/30/2026 777832867
Principal investigator 1 Allergan, Inc. $32,743.65 02/15/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004411
Principal investigator 1 Allergan, Inc. $30,857.90 01/20/2021 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004409
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,557.00 01/20/2021 Non-covered Recipient Entity
PRINCETON ALLERGY AND ASTHMA ASSOCIATES PA
A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. No dispute reported 06/30/2026 800641925
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $31.00 01/09/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249821
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $31.00 01/08/2021 Non-covered Recipient Entity
Princeton Center for Clinical Research
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma No dispute reported 06/30/2026 806249815